Key facts
- Daye’s last known valuation is $42.3M (Aug 2022).
- It has raised $32.6M; the latest was Later Stage VC ($2.3M) in Nov 2025.
- Notable investors include European Innovation Council, Khosla Ventures, Gaingels, Index Ventures, Salica Investments — 27 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 27 names
- ·Watchlist + deal alerts for Daye
- ·The full record, as it builds
Funding rounds
No funding rounds for Daye are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Daye
Operator of a gynecological health company intended for women's health and well-being. The company addresses the most prevalent, yet often overlooked, health conditions, from period and pelvic pain to cervical cancer prevention, enabling women to manage their gynecological health conveniently.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2017
- Employees
- 38
- Website
- yourdaye.com/
- Ownership
- Privately Held (backing)
Daye doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Daye shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Daye in its N-PORT filings yet. We sweep new filings monthly.